Drug intelligence / Profile preview

LY-3971297

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Recombinant Proteins and Enzymes, Peptides
Administration: Subcutaneous

Overview

LY-3971297 is a long-acting atrial natriuretic peptide (LA-ANP) analog under development by Eli Lilly for the treatment of obesity, hypertension, and heart failure. It is administered via subcutaneous injection and acts as an agonist of the natriuretic peptide receptor A (NPRA), also known as natriuretic peptide receptor 1. By activating NPRA, LY-3971297 promotes natriuresis—the excretion of sodium through urine—which can help reduce blood pressure and may contribute to weight loss by modulating fluid balance and metabolic processes. The drug is currently in Phase 1 clinical trials for both obesity and hypertension[1][2][4][5][6][7].

Other names: LA-ANPLong-Acting Atrial Natriuretic Peptide

Targets

NPR1 (Natriuretic peptide receptor 1)

Beyond the preview

Go deeper on LY-3971297.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY-3971297.

Explore the full profile